Answers are grounded in this paper and cite their sources.
Retraction reveals methodological flaws in randomized trial investigating prevention of ovarian hyperstimulation syndrome in IVF/ICSI cycles.
RETRACTION: Y.A. Bassiouny, D.M.R. Dakhly, Y.A. Bayoumi, N.A. Salaheldin, H.A. Gouda, and A.A. Hassan, "Randomized Trial of Combined Cabergoline And Coasting in Preventing Ovarian Hyperstimulation Syndrome During In Vitro Fertilization/intracytoplasmic Sperm Injection Cycles," International Journal of Gynecology & Obstetrics 140, no. 2 (2018): 217-222, https://doi.org/10.1002/ijgo.12360. This retraction has been issued for the above article, published online on 21 October 2017 in Wiley Online Library (wileyonlinelibrary.com), by agreement between the journal Editor-in-Chief, Michael Geary; and John Wiley & Sons Ltd. A third party expressed concerns about the randomization allocation process, noting that the reported methodology does not appear to reflect the standards of a randomized clinical trial. When asked for clarification, the authors provided their study data and explanation. However, the editorial team and publisher did not feel that the answers and data alleviated the concerns with the methodology. While the work may have been undertaken in good faith, it does not meet the minimum standards to constitute a randomized study. As a result, the data and conclusions are considered unreliable, and therefore the article must be retracted.
No takes yet. Share an insight, caveat, or question.
A 2026 study studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: